



TITLE:

Detection of endogenous and food-derived collagen dipeptide prolylhydroxyproline (Pro-Hyp) in allergic contact dermatitis-affected mouse ear.

AUTHOR(S):

Kusubata, Masashi; Koyama, Yoh-Ichi; Tometsuka, Chisa; Shigemura, Yasutaka; Sato, Kenji

CITATION:

Kusubata, Masashi ...[et al]. Detection of endogenous and food-derived collagen dipeptide prolylhydroxyproline (Pro-Hyp) in allergic contact dermatitis-affected mouse ear.. Bioscience, biotechnology, and biochemistry 2015, 79(8): 1356-1361

ISSUE DATE:

2015-04-07

URL:

<http://hdl.handle.net/2433/202882>

RIGHT:

This is an Accepted Manuscript of an article published by Taylor & Francis in 'Bioscience, biotechnology, and biochemistry' on 07 Apr 2015, available online: <http://www.tandfonline.com/10.1080/09168451.2015.1027653>; The full-text file will be made open to the public on 07 Apr 2016 in accordance with publisher's 'Terms and Conditions for Self-Archiving'; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ください。

1 Running title: Endogenous and food-derived Pro-Hyp in the ear

2

3 **Detection of endogenous and food-derived collagen dipeptide prolylhydroxyproline**

4 **(Pro-Hyp) in allergic contact dermatitis-affected mouse ear**

5

6 Masashi Kusubata¹, Yoh-ichi Koyama¹, Chisa Tometsuka¹, Yasutaka Shigemura^{2,3}, and

7 Kenji Sato^{2, 4*}

8 ¹*Research Institute of Biomatrix, Nippi Inc., Toride, Ibaraki 302-0017, Japan;* ²*Division*

9 *of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto*

10 *Prefectural University, 1-5 Shimogamo, Kyoto 606-8522, Japan;* ³*Department of*

11 *Nutrition, Faculty of Domestic Science, Tokyo Kasei University, 1-18-1 Kaga,*

12 *Itabashi-ku, Tokyo, 173-8602, Japan;* ⁴*Division of Applied Biosciences, Graduate*

13 *School of Agriculture, Kyoto University, Kitashirakawa Oiwake-cho, Kyoto 606 8502,*

14 *Japan.*

15

16

1 Addresses of authors

2 Masashi Kusubata Tel: +81-297-71-3043, E-mail: qusubata@nippi-inc.co.jp

3 Yoh-ichi Koyama, Tel: +81-297-71-3043, E-mail: ykoyama@nippi-inc.co.jp

4 Chis Tometsuka Tel: +81-297-71-3043, E-mail: c-toometsuka@nippi-inc.co.jp

5 Yasutaka Shigemura Tel: +81-3-3961-5629, E-mail: shigemura@tokyo-kasei.ac.jp

6 *Corresponding author: Kenji Sato, Tel: +81-75-753-6444, E-mail:

7 kensato@kais.kyoto-u.ac.jp

8

9

10

11

12

13

14

15

16

1 **Abstract**

2 Generation of collagen dipeptides and deposition of orally administered
3 prolylhydroxyproline (Pro-Hyp) in local inflammatory sites were examined in mice
4 with hapten (2,4-dinitrofluorobenzene)-induced dermatitis in the ear. Pro-Hyp content in
5 the hapten-treated ear was significantly higher in the chronic phase of contact dermatitis
6 than the vehicle control. In contrast, hydroxyprolylglycine (Hyp-Gly) contents remained
7 at lower levels in all cases compared to Pro-Hyp. Four hours after the ingestion of
8 [¹³C₅, ¹⁵N]Pro and [¹³C₅, ¹⁵N]Pro-Hyp, labeled-Pro-Hyp and Pro, respectively, appeared
9 only in the ear with dermatitis. Thus, Pro-Hyp is generated and degraded as part of the
10 rapid synthesis and degradation of collagen in the ear with dermatitis. In addition to the
11 endogenously generated Pro-Hyp, the orally administered Pro-Hyp was deposited in the
12 ears.

13
14 Key words: collagen peptide; prolylhydroxyproline; hydroxyprolylglycine; dermatitis;
15 inflammation.

16

1 Introduction

2 Collagen is one of the main protein components in the extracellular matrix and is
3 the most abundant protein in the body comprising about one-third of the total protein.¹⁾
4 Heat-denatured collagen extracted from skin, bone or fish scale is referred to as gelatin.
5 Collagen peptide, prepared by limited digestion of gelatin with proteases, is widely used
6 as a food supplement to improve conditions pertaining to the skin and joints. Recent
7 placebo-controlled double-blind trials have demonstrated that ingestion of collagen
8 peptide significantly improves skin and joint conditions.²⁻⁴⁾ Preclinical studies using
9 animal models have also demonstrated that ingestion of collagen peptide or gelatin
10 thickens collagen fibrils,^{5,6)} promotes healing of pressure ulcers⁷⁾ and bone fracture,⁸⁾
11 and increases bone mineral density.^{9,10)}

12 Presence of food-derived collagen oligopeptides in human peripheral blood after the
13 ingestion of collagen peptide has been studied.¹¹⁻¹⁴⁾ Prolylhydroxyproline (Pro-Hyp) has
14 been identified as major constituents of food-derived collagen peptide in human
15 blood.^{11,12,14)} Pro-Hyp has been demonstrated to stimulate the growth of primary
16 cultured mouse skin fibroblasts on collagen,¹⁵⁾ enhance the production of hyaluronic

1 acid by human skin fibroblasts,¹⁶⁾ modulate lipid metabolism in adipocytes,¹⁷⁾ and
2 suppress mineralization in chondrocytes.¹⁸⁾ Another collagen-derived dipeptide,
3 hydroxyprolylglycine (Hyp-Gly), was also reported to stimulate growth of skin
4 fibroblasts on collagen.¹³⁾ These studies suggest that the beneficial effects of ingestion
5 of collagen peptide depends, at least in part, on the biological activities of these
6 collagen oligopeptides.

7 Free and peptide forms of Hyp have been detected in the urine of growing
8 children,¹⁹⁾ patients with bone tumors,²⁰⁾ and rheumatoid arthritis patients.²¹⁾ These
9 studies indicate that collagen peptides are generated by extensive degradation of
10 extracellular matrix and under systemic inflammation. In the restricted site with
11 inflammation or damage, Pro-Hyp may be locally generated, which can stimulate
12 fibroblast growth for tissue repair and reconstruction of the extracellular matrix.
13 However, local production of collagen oligopeptides at the damaged site has not been
14 reported.

15 The objectives of the present study were to detect the local generation of Pro-Hyp
16 and Hyp-Gly in the restricted site with inflammation and to detect the deposition of

1 orally administered Pro-Hyp by using mice with hapten-induced contact dermatitis in
2 the ear.

4 **Materials and Methods**

5 *Chemicals.* Pro-Hyp and Hyp-Gly were obtained from Bachem (Bubendorf,
6 Switzerland). [$^{13}\text{C}_5$, ^{15}N]Pro-Hyp and [$^{13}\text{C}_5$, ^{15}N]Pro were obtained from Anygen,
7 (Jeollanam-do, Korea) and Cambridge Isotope Laboratories (Tewksbury, MA, USA),
8 respectively. 2,4-Dinitrofluorobenzene (DNFB) was obtained from Sigma-Aldrich (St.
9 Louis, MO, USA). All reagents were of analytical grade or better.

10 *Animal experiments.* All animal experiments in this study were approved by the
11 Ethics Committee of Nippi (Tokyo, Japan) and were carried out in the animal facilities
12 of Nippi. Specific pathogen-free female BALB/cAJcl mice (age, 7 weeks) were
13 purchased from CLEA Japan (Tokyo, Japan) and maintained at $23^\circ\text{C}\pm 5^\circ\text{C}$ on a
14 12-h/12-h light-dark cycle throughout the experimental period. The mice were fed a
15 standard diet (MF; Oriental Yeast, Tokyo, Japan). One day before the determination of
16 collagen dipeptide contents (for Pro-Hyp and Hyp-Gly), the diet was changed to

collagen-free AIN-93M (Oriental Yeast). Mice were given tap water *ad libitum*.

Induction of allergic contact dermatitis was performed by the method described by Kusubata et al.²²⁾ Briefly, after 1 week of acclimatization, the mice were treated with 10 μ L of 0.2% DNFB in acetone every 3 days to both dorsal and ventral sides of the right ear for 9 or 18 days to induce allergic contact dermatitis. Control mice received the treatment with acetone. Ear thickness was measured using a dial thickness gauge (Ozaki MFG, Tokyo, Japan) to evaluate development of edema by contact dermatitis²³⁾.

To estimate the absorption of Pro-Hyp into blood, Pro-Hyp was orally administered. The diet was changed from MF to AIN-93M (collagen-free) in the morning on the day prior to Pro-Hyp administration, and the mice were fasted overnight. Pro-Hyp was dissolved in water at a concentration of 1 mg/mL and orally administered to mice via gavage ($400 \mu\text{g} \cdot 400 \mu\text{L}^{-1} \cdot 20 \text{ g body weight}^{-1}$). This dose was employed on the basis of our previous human trial (collagen peptide $0.2 \text{ g} \cdot \text{kg body weight}^{-1} \cdot \text{day}^{-1}$)^{5,6)} and the frequency of Pro-Hyp motif in collagen (10%). After Pro-Hyp administration, the mice were allowed to ingest AIN-93M *ad libitum*. Blood was collected 0, 0.5, 1, 2, 4 h after administration.

1 To detect the deposition of orally administered Pro-Hyp in the ear, stable isotope
2 labeled [$^{13}\text{C}_5$, ^{15}N]Pro-Hyp or [$^{13}\text{C}_5$, ^{15}N]Pro were administered to mice receiving DNFB
3 application on the right ear. The diet was changed from MF to AIN-93M on day 17 as
4 described above, and mice were fasted overnight. On day 18, 400 μg ·400 μL /20 g body
5 weight of the labeled Pro-Hyp or Pro in water was administered to mice via gavage.
6 Ears were collected 4 h after the administration.

7
8 *Preparation of plasma and ear samples.* Mice were anesthetized with diethyl ether
9 and blood samples were collected from the left ventricle by using a heparinized needle
10 and syringe. After centrifugation at 12,000 rpm for 20 min at 4°C, plasma was collected
11 and stored at -80°C until use. Plasma samples were mixed with three volumes of
12 ethanol. The resultant precipitate was removed by centrifugation. The supernatant was
13 diluted in 20 volumes of 0.1% formic acid and subjected to liquid
14 chromatography-tandem mass spectrometry (LC-MS/MS) analysis.

15 The ears were excised and stored in 10 volumes of 70% ethanol at -80°C until use.
16 They were cut into small pieces by using scissors and homogenized with a BioMasher 2

1 (Nippi, Tokyo, Japan) in 70% ethanol. After centrifugation at 12,000 rpm for 20 min at
2 4°C, the supernatant was collected and dried using a centrifugal concentrator. The dried
3 material was dissolved in 0.4 mL of 0.1% formic acid and centrifuged at 12,000 rpm for
4 20 min at 4°C. The supernatant was filtrated through a 0.45- μ m membrane filter and
5 subjected to LC-MS/MS analysis.

6
7 *LC-MS/MS analysis.* Multiple reaction monitoring (MRM) was carried out to
8 determine the amount of each compound by using 3200 QTRAP (AB Sciex,
9 Framingham, MA, USA) equipped with HPLC Agilent1200 (Agilent, Santa Clara, CA,
10 USA), monitoring the transition of m/z 235–75 ($^{13}\text{C}_5$, ^{15}N -Pro-Hyp), m/z 229–70
11 (Pro-Hyp), m/z 189–86 (Hyp-Gly), m/z 132–68 (Hyp), m/z 122–75 ($^{13}\text{C}_5$, ^{15}N -Pro), and
12 m/z 116–70 (Pro). HPLC was performed according to Yoshida et al.²⁴⁾ with minor
13 modifications. The ion source was set with values of curtain gas of 15.0 psi, collision
14 gas of 5 psi, ion spray voltage of 3,000 V, temperature of 600°C, ion source gas 1 of 80
15 psi, and ion source gas 2 of 80 psi. The peak area was calculated using Analyst 1.5 (AB
16 Sciex, Framingham, MA, USA).

1 *Statistical analysis.* Statistical differences illustrated in Fig. 2 were detected using
2 the Tukey–Kramer test, and the difference was considered to be significant when $p <$
3 0.05. Statistical differences illustrated in Fig. 4 were assessed using the paired t -test, and
4 $p < 0.05$ was considered significant.

5 6 **Results**

7 *Endogenous generation of Pro-Hyp in the ear with dermatitis.* Temporal changes
8 in the thickness of DNFB- and vehicle-treated ears are shown in Fig. 1. Treatment with
9 the vehicle did not induce thickening of the ear. In contrast, repeated treatment with
10 DNFB induced a marked increase in ear thickness in the acute phase (days 3–12). In the
11 chronic phase (after day 15), the ear thickness decreased slightly and remained constant
12 thereafter as reported previously.²²⁾ **Thus, contact allergic dermatitis was induced in the**
13 **right ear. The mice in this experiment were fed collagen-free diet and subjected to**
14 **detection of Pro-Hyp and Hyp-Gly in the ears.**

15 As shown in Fig. 2A and C, there was no significant difference in Hyp-Gly content
16 between the DNFB- and vehicle-treated groups in the acute (day 9) and chronic phases

(day 18). Higher contents of Pro-Hyp compared to Hyp-Gly were detected even in the non-treated left ears (Fig. 2A and B). Pro-Hyp content in the DNFB-treated right ear increased to approximately 2-fold in the acute phase (day 9) and 7-fold in the chronic phase (day 18) compared to the vehicle-treated right ear (Fig. 2D).

Metabolism of orally administered Pro-Hyp and Pro in the ear. To evaluate the deposition of orally administered Pro-Hyp in ears, Pro-Hyp levels in the plasma after ingestion of Pro-Hyp at 400 $\mu\text{g}/20\text{ g}$ body weight was first examined. As shown in Fig. 3, plasma Pro-Hyp levels increased sharply 0.5 h after administration and returned to the initial levels 4 h after administration. Therefore, deposition of orally administered Pro-Hyp and Pro in the ear with the dermatitis was examined 4 h after oral administration. As shown in Fig. 4A and B, no significant amounts of the labeled Pro-Hyp and Pro were detected in the ears from either side in mice receiving water. Labeled Pro-Hyp (Fig. 4A) and Pro (Fig. 4B) were detected in the both DNFB-treated right ears and non-treated left ears after the administration of labeled Pro-Hyp and Pro, respectively. On the other hand, the labeled Pro-Hyp (Fig. 4A) and Pro (Fig. 4B) were specifically detected in the DNFB-treated right ears after the administration of labeled

1 Pro and Pro-Hyp, respectively.

2

3 **Discussion**

4 Under bone metastasis of cancer and chronic and systemic inflammatory
5 disorders such as rheumatoid arthritis, increase in free Hyp and Hyp-containing peptides,
6 including Pro-Hyp, in blood and urine have been reported.^{20,21)} In such cases, extensive
7 degradation of collagen occurs and the resultant collagen peptides can be detected in
8 blood and urine. However, increase in these collagen oligopeptides in blood and urine
9 from the animals and human suffering from local and restricted inflammation has not
10 been reported. The present study demonstrates the local generation of Pro-Hyp in the
11 right ear with dermatitis without affecting Pro-Hyp level in the normal left ear of the
12 same animal. Hyp-Gly appears in human peripheral blood at a relatively high
13 concentration after ingestion of collagen peptide.¹³⁾ However, no significant increase of
14 Hyp-Gly was observed in the mouse ears both with and without contact dermatitis,
15 which might be explained by the reduced production of Hyp-Gly from collagen by
16 mouse proteases and peptidases or rapid metabolism of Hyp-Gly.

1 After ingestion of the stable isotope-labeled Pro-Hyp, the labeled Pro was detected
2 only in the ear with dermatitis, indicating that prolydase, which splits dipeptides that
3 contain carboxyl-terminal proline or hydroxyproline, is activated in the ear with the
4 dermatitis. The activation and increase of prolydase in rat under inflammatory
5 conditions have been reported.²⁵⁾ The present study also demonstrates that the stable
6 isotope-labeled Pro is incorporated into the Pro-Hyp as early as within 4 h, but only in
7 the ear with the dermatitis. This indicates that orally administered Pro is incorporated
8 into collagen molecule and that Pro-Hyp is generated from the newly synthesized
9 collagen within 4 h. The prolydase can, therefore, provide Pro for collagen synthesis. As
10 part of this very rapid synthesis and degradation of collagen in the ear with dermatitis,
11 collagen peptides are simultaneously generated and degraded, which results in specific
12 and local increase of Pro-Hyp in the ear with dermatitis.

13 It has been reported that Pro-Hyp increases the number of fibroblasts migrated
14 from the explanted mouse skin and that it enhances the proliferation of mouse skin
15 fibroblasts on collagen gel; these have been considered as wound healing models.¹⁵⁾
16 Therefore, Pro-Hyp that was locally generated at the inflammatory site can trigger

1 fibroblast growth for local tissue reconstruction.

2 Pro-Hyp appears as a major food-derived collagen peptide in human blood after the

3 ingestion of collagen peptide.¹¹⁾ The present study also indicates that an increase in

4 Pro-Hyp in mouse plasma after the ingestion of 0.02 g/kg Pro-Hyp, which is equivalent

5 to 0.2 g/kg body weight of collagen peptide. The maximum level of Pro-Hyp in the

6 plasma is approximately 2 μ M, which is considerably lower compared to that in human

7 plasma (approximately 20 μ M) after the ingestion of similar dose of collagen peptide

8 (10 g/serving).¹¹⁾ The plasma Pro-Hyp level returned to the initial level 4 h after the

9 administration, after the orally administered Pro-Hyp was cleared from the plasma.

10 However, the labeled Pro-Hyp remained in the ears both with and without dermatitis,

11 which indicates that the orally administered Pro-Hyp deposits in the ear. Therefore, oral

12 administration of collagen peptide can affect the Pro-Hyp level in the inflammatory site

13 and cooperatively act with the endogenously generated Pro-Hyp on fibroblasts and other

14 cells in the inflammatory site for the reconstruction of the extracellular matrix. **In fact,**

15 **oral administration of collagen peptide enhance wound healing of pressure ulcer in**

16 **animal model possibly due to enhanced growth of fibroblast.²⁶⁾ On the other hand,**

1 effect of administration of collagen peptide on immune response itself remains to be
2 solved.

3 As shown in Fig. 1, swelling occurred in the ear with dermatitis. Therefore,
4 accumulation of Pro-Hyp-containing fluid in the ear with the dermatitis is expected.
5 However, there is no significant difference in the level of labeled Pro-Hyp between the
6 ear with and without dermatitis 4 h after the administration, which is partially explained
7 by the specific degradation of Pro-Hyp by prolidase in the ear with dermatitis as
8 discussed above. In addition, Kawaguchi et al. demonstrated that orally administered
9 [^{14}C] Pro-Hyp deposits in a peptide form in rat tissues and is rapidly converted into
10 unidentified metabolites that were or were not susceptible to HCl hydrolysis ²⁷⁾. It is
11 possible that Pro-Hyp is rapidly converted into these unidentified metabolites with some
12 biological activities in the ear with dermatitis compared to the normal ear. To address
13 these problems at the molecular level, it is necessary to identify the metabolites.
14 Currently, further studies to identify the metabolites of Pro-Hyp and Hyp-Gly in animal
15 tissues and in cultured fibroblast are underway.

16

1 **Acknowledgements**

2 The authors are grateful to Dr. O. Hayashida for his valuable discussions.

3 This work was partially supported by a JSPS Grant-in-Aid for Scientific Research (C)
4 to Kenji Sato (No.23500966).

5

6 **References**

7 [1] Eastoe JE. Composition of collagen and allied proteins. In: Treaties on Collagen.

8 Ramachandram GN ed, Academic Press, London and New York, 1976.

9 [2] Clark KL, Sebastianelli W, Flechsenhar KR, Aukermann DF, Meza F, Millard RL,

10 Deitch JR, Sherbondy PS, Albert A. 24-Week study on the use of collagen

11 hydrolysate as a dietary supplement in athletes with activity-related joint pain.

12 Curr. Med. Res. Opin. 2008;24:1485-1496.

13 [3] Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral

14 supplementation of specific collagen peptides has beneficial effects on human

15 skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol.

16 Physiol. 2014; 27:47-55.

- 1 [4] Proksch E, Schunck M, Zague V, Segger D, Degwert J, Oesser S. Oral intake of
2 specific bioactive collagen peptides reduces skin wrinkles and increases dermal
3 matrix synthesis. *Skin Pharmacol. Physiol.* 2014;27:113-119.
- 4 [5] Matsuda N, Koyama Y, Hosaka Y, Ueda H, Watanabe T, Araya T, Irie S, Takehana K.
5 Effects of ingestion of collagen peptide on collagen fibrils and
6 glycosaminoglycans in the dermis. *J. Nutr. Sci. Vitaminol.* 2006;52:211-215.
- 7 [6] Minaguchi J, Koyama Y, Meguri N, Hosaka Y, Ueda H, Kusubata M, Hirota A, Irie
8 S, Mafune N, Takehana K. Effects of ingestion of collagen peptide on collagen
9 fibrils and glycosaminoglycans in Achilles tendon. *J. Nutr. Sci. Vitaminol.*
10 2005;51:169-174.
- 11 [7] Nakao K, Kusubata M, Hara K, Igarashi m, Yamazaki N, Koyama Y. Effects of
12 collagen peptide ingestion on healing of skin wound in a rat model of pressure
13 ulcer. *Jpn. Pharmacol. Ther.* 2013;41:587-596.
- 14 [8] Tsuruoka N, Yamamoto R, Sakai Y, Yoshitake Y, Yonekura H. Promotion by
15 collagen tripeptide of type I collagen gene expression in human osteoblastic cells
16 and fracture healing of rat femur. *Biosci. Biotechnol. Biochem.* 2007;71:2680–

- 1 2687.
- 2 [9] Koyama Y, Hirota A, Mori H, Takahara H, Kuwaba K, Kusubata M, Matsubara Y,
- 3 Kasugai S, Itoh M, Irie S. Ingestion of gelatin has differential effect on bone
- 4 mineral density and body weight in protein undernutrition. J. Nutr. Sci. Vitaminol.
- 5 2001;47:84-86.
- 6 [10] Wu J, Fujioka M, Sugimoto K, Mu G, Ishimi Y. Assessment of effectiveness of oral
- 7 administration of collagen peptide on bone metabolism in growing and mature
- 8 rats. Bone Miner. Metab. 2004;22:547-553.
- 9 [11] Iwai K, Hasegawa T, Taguchi Y, Morimatsu F, Sato K, Nakamura Y, Higashi A,
- 10 Kido Y, Nakabo Y, Ohtsuki K. Identification of food-derived collagen peptides in
- 11 human blood after oral ingestion of gelatin hydrolysates. J. Agric. Food Chem.
- 12 2005;53:6531-6536.
- 13 [12] Ichikawa S, Morifuji M, Ohara H, Matsumoto H, Takeuchi Y, Sato, K.
- 14 Hydroxyproline-containing dipeptides and tripeptides quantified at high
- 15 concentration in human blood after oral administration of gelatin hydrolysate. Int.
- 16 J. Food Sci. Nutri. 2010;61:52-60.

- 1 [13] Shigemura Y, Akaba S, Kawashima E, Park EY, Nakamura Y, Sato K. Identification
- 2 of a novel food-derived collagen peptide, hydroxyprolyl-glycine, in human
- 3 peripheral blood by pre-column derivatisation with isothiocyanate. Food Chem.
- 4 2011;129:1019-1024.
- 5 [14] Ohara H, Matsumoto H, Ito K, Iwai K, Sato, K. Comparison of quantity and
- 6 structures of hydroxyproline-containing peptides in human blood after oral
- 7 ingestion of gelatin hydrolysates from different sources. J. Agric. Food Chem.
- 8 2007;55:1532-1535.
- 9 [15] Shigemura Y, Iwai K, Morimatsu F, Iwamoto T, Mori T, Oda C, Taira T, Park EY,
- 10 Nakamura Y, Sato, K. Effect of prolyl-hydroxyproline (Pro-Hyp), a food-derived
- 11 collagen peptide in human blood, on growth of fibroblasts from mouse skin. J.
- 12 Agric. Food Chem. 2009;57:444-449.
- 13 [16] Ohara H, Ichikawa S, Matsumoto H, Akiyama M, Fujimoto N, Kobayashi T,
- 14 Tajima S. Collagen-derived dipeptide, proline-hydroxyproline, stimulates cell
- 15 proliferation and hyaluronic acid synthesis in cultured human dermal fibroblasts. J.
- 16 Dermatol. 2010;37:330-338.

- 1 [17] Minaguchi J, Tometsuka C, Koyama Y, Kusubata M, Nagayasu A, Sawaya S, Shiga
- 2 T, Shima H, Hara T, Takehana K. Effects of collagen-derived oligopeptide
- 3 prolylhydroxyproline on differentiation of mouse 3T3-L1 preadipocytes. Food Sci.
- 4 Technol. Res. 2012;18:593-599.
- 5 [18] Nakatani S, Mano H, Sampei C, Shimizu J, Wada M. Chondroprotective effect of
- 6 the bioactive peptide prolyl-hydroxyproline in mouse articular cartilage in vitro
- 7 and in vivo. Osteoarthritis Cartilage 2009;17:1620-1627.
- 8 [19] Ziff M, Kibrick A, Dresner E, Gribetz J. Excretion of hydroxyproline in patients
- 9 with rheumatic and non-rheumatic diseases. J. Clin. Invest. 1956;35:579-587.
- 10 [20] Hosley HF, Taft EG, Olson KB, Gates S, Beebe RT. Hydroxyproline excretion in
- 11 malignant neoplastic disease. Arch. Intern. Med. 1966;118:565-71.
- 12 [21] Bienenstock H, Kibrick AC. Urinary excretion of prolylhydroxyproline in
- 13 rheumatic diseases. Ann. Rheum. Dis. 1969;28:28-30.
- 14 [22] Kusubata M, Hirota A, Ebihara T, Kuwaba K, Matsubara Y, Sasaki T, Kusakabe M,
- 15 Tsukada T, Irie S, Koyama Y. Spatiotemporal changes of fibronectin, tenascin-C,
- 16 fibulin-1, and fibulin-2 in the skin during the development of chronic contact

- 1 dermatitis. J. Invest. Dermatol. 1999;113:906-912.
- 2 [23] Gorbachev AV, Fairchild RL. Induction and regulation of T-cell priming for contact
- 3 hypersensitivity. Crit. Rev. Immunol. 2001;21:451-472.
- 4 [24] Yoshida H, Mizukoshi T, Hirayama K, Miyano H. Comprehensive analytical
- 5 method for the determination of hydrophilic metabolites by high-performance
- 6 liquid chromatography and mass spectrometry. J. Agric. Food Chem.
- 7 2007;55:551-560.
- 8 [25] Imai K, Nagatsu T, Yajima T, Maeda N, Kumegawa M, Kato T. Developmental
- 9 changes in the activities of prolinase and prolidase in rat salivary glands, and the
- 10 effect of thyroxine administration. Mol. Cell Biochem. 1982;42:31-36.
- 11 [26] Nakao K, Kusubata M, Hara K, Igarashi, M, Yamazaki N, Koyama Y. Effects of
- 12 collagen peptide ingestion on healing of skin wound in a rat model of pressure
- 13 ulcer. Jpn. Pharmacol. Ther. 2013;41:587-595.
- 14 [27] Kawaguchi T, Nanbu PN, Kurokawa M. Distribution of prolylhydroxyproline and
- 15 its metabolites after oral administration in rats. Biol. Pharm. Bull.
- 16 2012;35:422-427.

1 **Figure legends**

2 Fig. 1. Induction of contact dermatitis

3 Contact dermatitis was induced by applying DNFB or vehicle every 3 days to the right
4 ear of mice and the temporal changes of ear thickness were measured. The results are
5 presented as mean \pm SD (n=6).

6

7 Fig.2. Contents of Hyp-Gly and Pro-Hyp in mouse ear

8 (A, B): Hyp-Gly (A) and Pro-Hyp (B) in the non-treated left ear of mice treated with
9 vehicle (V) or DNFB on the right ear for 9 or 18 days. (C, D): Hyp-Gly (C) and
10 Pro-Hyp (D) in the right ear treated with vehicle (V) or DNFB for 9 or 18 days. The
11 results are presented as mean \pm SD (n=6). Values in the same figure not sharing a
12 common letter above the bar are significantly different from each another, $p < 0.05$.

13

14 Fig. 3. Pro-Hyp in plasma after ingestion of Pro-Hyp

15 Pro-Hyp was orally administered at a dose of 400 μ g/20 g body weight and measured in
16 the plasma. The results are presented as mean \pm SD (n=3)

1

2 Fig. 4: Contents of [$^{13}\text{C}_5, ^{15}\text{N}$]Pro-Hyp and [$^{13}\text{C}_5, ^{15}\text{N}$]Pro in the ears of mice with contact
3 dermatitis

4 The right ear of mice was treated with DNFB (+) and the left ear was non-treated (–) for
5 18 days. On day 18, the mice were orally administered water, [$^{13}\text{C}_5, ^{15}\text{N}$]Pro-Hyp or
6 [$^{13}\text{C}_5, ^{15}\text{N}$]Pro, and the contents of the labeled Pro-Hyp (A) and Pro (B) in each ear were
7 determined 4 h after ingestion (n=4). * p < 0.05.




Fig. 1

Fig. 1. Induction of contact dermatitis
Contact dermatitis was induced by applying DNFB or vehicle every 3 days to the right ear of mice and the temporal changes of ear thickness were measured. The results are presented as mean \pm SD (n=6).

254x190mm (72 x 72 DPI)




Fig. 2

Fig.2. Contents of Hyp-Gly and Pro-Hyp in mouse ear
(A, B): Hyp-Gly (A) and Pro-Hyp (B) in the non-treated left ear of mice treated with vehicle (V) or DNFB on the right ear for 9 or 18 days. (C, D): Hyp-Gly (C) and Pro-Hyp (D) in the right ear treated with vehicle (V) or DNFB for 9 or 18 days. The results are presented as mean \pm SD (n=6). Values in the same figure not sharing a common letter above the bar are significantly different from each another, $p < 0.05$.

254x338mm (72 x 72 DPI)




Fig. 3

Fig. 3. Pro-Hyp in plasma after ingestion of Pro-Hyp
Pro-Hyp was orally administered at a dose of 400 μ g/20 g body weight and measured in the plasma. The results are presented as mean \pm SD (n=3)

254x190mm (72 x 72 DPI)





Fig. 4

Fig. 4: Contents of $[^{13}\text{C}_5, ^{15}\text{N}]\text{Pro-Hyp}$ and $[^{13}\text{C}_5, ^{15}\text{N}]\text{Pro}$ in the ears of mice with contact dermatitis. The right ear of mice was treated with DNFB (+) and the left ear was non-treated (-) for 18 days. On day 18, the mice were orally administered water, $[^{13}\text{C}_5, ^{15}\text{N}]\text{Pro-Hyp}$ or $[^{13}\text{C}_5, ^{15}\text{N}]\text{Pro}$, and the contents of the labeled Pro-Hyp (A) and Pro (B) in each ear were determined 4 h after ingestion (n=4). * $p < 0.05$.

158x211mm (72 x 72 DPI)



158x119mm (72 x 72 DPI)

Review